The final draft guidance applies to RRMM patients in England and Wales who have received at least three lines of therapy, including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody, and have progressed on their last treatment.
NICE’s latest decision updates its positive but restricted draft guidance on Tecvayli in July, which limited the use of the drug to patients who would otherwise be offered pomalidomide plus dexamethasone (pom-dex)…
